Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk.

European heart journal open Pub Date : 2024-08-31 eCollection Date: 2024-09-01 DOI:10.1093/ehjopen/oeae064
Tarek Harb, Efthymios Ziogos, Roger S Blumenthal, Gary Gerstenblith, Thorsten M Leucker
{"title":"Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk.","authors":"Tarek Harb, Efthymios Ziogos, Roger S Blumenthal, Gary Gerstenblith, Thorsten M Leucker","doi":"10.1093/ehjopen/oeae064","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Lipoprotein(a) [Lp(a)] levels are predominantly genetically determined and repeat measurements are generally considered unlikely to be clinically useful. However, the temporal variation of Lp(a) is not well characterized. Our aim was to determine the intra-individual variability of Lp(a) and whether a repeated measure reclassified Lp(a)-specific cardiovascular risk using the European Atherosclerosis Society (EAS) consensus statement risk categories.</p><p><strong>Methods and results: </strong>This retrospective cohort study analysed initial and repeated serum Lp(a) levels measured using the same methodology from 609 individuals in the Nashville Biosciences database, a de-identified electronic medical records database. Baseline and follow-up paired values were significantly different (<i>P</i> < 0.05), with an absolute change of ≥10 mg/dL in 38.1% [95% CI 34.2-42%] and a >25% change in 40.5% [95% CI 36.6-44.3%] of individuals. Although the categories of those whose values were in the EAS low-risk and high-risk categories did not change, 53% of those in the intermediate 'grey-zone' category transitioned to either the low-risk (20%) or high-risk (33%) category. Black individuals exhibited greater variability than White individuals and women exhibited greater variability than men. There was a positive correlation between the baseline Lp(a) levels and the absolute changes in Lp(a), (<i>r</i> = 0.59, <i>P</i> < 0.01).</p><p><strong>Conclusion: </strong>Temporal-related changes in Lp(a) variability were present in many individuals. A repeat Lp(a) measure may allow more precise Lp(a)-specific cardiovascular risk prediction for individuals whose initial value is in the EAS-defined intermediate 'grey-zone' category. Lp(a) variability should be included in calculating the expected effect sizes in future clinical research studies targeting Lp(a).</p>","PeriodicalId":93995,"journal":{"name":"European heart journal open","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365507/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European heart journal open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ehjopen/oeae064","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: Lipoprotein(a) [Lp(a)] levels are predominantly genetically determined and repeat measurements are generally considered unlikely to be clinically useful. However, the temporal variation of Lp(a) is not well characterized. Our aim was to determine the intra-individual variability of Lp(a) and whether a repeated measure reclassified Lp(a)-specific cardiovascular risk using the European Atherosclerosis Society (EAS) consensus statement risk categories.

Methods and results: This retrospective cohort study analysed initial and repeated serum Lp(a) levels measured using the same methodology from 609 individuals in the Nashville Biosciences database, a de-identified electronic medical records database. Baseline and follow-up paired values were significantly different (P < 0.05), with an absolute change of ≥10 mg/dL in 38.1% [95% CI 34.2-42%] and a >25% change in 40.5% [95% CI 36.6-44.3%] of individuals. Although the categories of those whose values were in the EAS low-risk and high-risk categories did not change, 53% of those in the intermediate 'grey-zone' category transitioned to either the low-risk (20%) or high-risk (33%) category. Black individuals exhibited greater variability than White individuals and women exhibited greater variability than men. There was a positive correlation between the baseline Lp(a) levels and the absolute changes in Lp(a), (r = 0.59, P < 0.01).

Conclusion: Temporal-related changes in Lp(a) variability were present in many individuals. A repeat Lp(a) measure may allow more precise Lp(a)-specific cardiovascular risk prediction for individuals whose initial value is in the EAS-defined intermediate 'grey-zone' category. Lp(a) variability should be included in calculating the expected effect sizes in future clinical research studies targeting Lp(a).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
脂蛋白(a)的个体内变异性:重复测量对中危个体重新分类的价值。
目的:脂蛋白(a)[Lp(a)]水平主要由基因决定,一般认为重复测量不会对临床有用。然而,脂蛋白(a)的时间变化特征并不明显。我们的目的是确定脂蛋白(a)的个体内变异性,以及重复测量是否能根据欧洲动脉粥样硬化协会(EAS)共识声明的风险类别对脂蛋白(a)特异性心血管风险进行重新分类:这项回顾性队列研究分析了纳什维尔生物科学数据库(一个去标识化的电子病历数据库)中使用相同方法测量的 609 人的初始和重复血清脂蛋白(a)水平。基线值和随访配对值有显著差异(P < 0.05),38.1% [95% CI 34.2-42%]的人绝对值变化≥10 mg/dL,40.5% [95% CI 36.6-44.3%]的人变化>25%。虽然处于 EAS 低风险和高风险类别的人的类别没有发生变化,但处于中间 "灰色地带 "类别的人中有 53% 过渡到了低风险(20%)或高风险(33%)类别。黑人的变异性大于白人,女性的变异性大于男性。Lp(a) 的基线水平与 Lp(a) 的绝对变化呈正相关(r = 0.59,P < 0.01):结论:许多人的脂蛋白(a)变异性存在与时间相关的变化。对于初始值处于 EAS 界定的中间 "灰色区域 "类别的个体,重复测量 Lp(a)可更准确地预测 Lp(a)特异性心血管风险。在未来针对脂蛋白(a)的临床研究中,计算预期效应大小时应将脂蛋白(a)变异性包括在内。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
0
期刊最新文献
The incidence of atrial fibrillation detected by implantable loop recorders: a comparison between patients with and without embolic stroke of undetermined source. Intra-individual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate risk. New data allow to better understand the secrets of lipoprotein(a): is that for sure? Correction to: Correlates and consequences of atrial fibrillation in a prospective study of 25 000 participants in the China Kadoorie Biobank. Colchicine for cardiovascular and limb risk reduction in Medicare beneficiaries with peripheral artery disease: emulation of target trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1